EHEmrullah Hayta

Emrullah Hayta

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Emrullah Hayta has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Altered Circulating Biomarkers of Purinergic Signaling, Inflammasome-Related Pathways, Pyroptosis, and Oxidative Stress in Fibromyalgia

    by Emrullah Hayta, Tugba Agbektas, Gonca Kabak, Gokhan Dogan, Ayca Tas, Yavuz Silig

    (1) Fibromyalgia syndrome (FMS) is a chronic pain disorder with a multifactorial pathogenesis involving neuroinflammation, oxidative stress, and immune dysfunction. This study aimed to evaluate serum biomarkers related to purinergic signaling, inflammasome activation, pyroptosis, and oxidative stress in patients with FMS. (2) Methods: A total of 93 patients with FMS and 93 age- and sex-matched healthy controls were enrolled. Serum levels of pannexin-1 (PANX1), purinergic receptor P2X7 (P2RX7), NLRP3, caspase-1 (CASP1), interleukin-1β (IL-1β), interleukin-18 (IL-18), gasdermin D (GSDMD), and gasdermin E (GSDME) were measured using enzyme-linked immunosorbent assays (ELISA). (3) Results: Total antioxidant status (TAS) and total oxidant status (TOS) were determined. Patients with FMS exhibited significantly increased serum CASP1, GSDME, PANX1, P2RX7, and total oxidative stress (TOS) levels, whereas GSDMD, NLRP3, IL-18, and TAS levels were significantly decreased compared with controls (all p < 0.05). No significant differences were observed in IL-1β levels. Receiver operating characteristic analysis demonstrated exploratory discriminatory performance within this case–control cohort for CASP1 and TAS (AUC = 0.898), followed by TOS (AUC = 0.849) and P2RX7 (AUC = 0.757). (4) Conclusions: These findings indicate alterations in circulating biomarkers related to purinergic signaling, inflammasome-associated pathways, pyroptosis-related proteins, and oxidative stress in patients with FMS. These alterations may contribute to the pathophysiology of FMS and provide a foundation for future mechanistic studies investigating their potential as biomarkers and therapeutic targets.

  • Serum ADAM12 as a Biomarker in Fibromyalgia Syndrome: Inflammatory and Clinical Correlates

    by Tugba Agbektas, Emrulah Hayta, Yavuz Siliğ

    Fibromyalgia syndrome (FMS) is characterized by widespread pain accompanied by fatigue, sleep disturbance, and cognitive symptoms. This cross-sectional study included 44 patients with FMS and 43 age- and gender-matched healthy controls. Serum A Disintegrin and Metalloprotease 12 (ADAM12) levels were measured by immunoassay, and clinical features were recorded. ADAM12 concentrations were significantly higher in the FMS group than in controls (1041.15 ± 565.09 ng/L vs. 834.05 ± 365.56 ng/L; p = 0.004). ROC analysis showed modest diagnostic performance (AUC = 0.678; p = 0.004). Sleep disturbance, fatigue, and concentration difficulties were more prevalent in patients. Family history of FMS occurred only in patients and was associated with higher ADAM12 (p = 0.010). ADAM12 also correlated with age (p = 0.047) and family history (p = 0.024). ADAM12, despite its limited standalone diagnostic value, emerges as a promising supplementary biomarker in FMS, with its elevation and clinical associations underscoring the need for further validation in longitudinal studies.

  • Open Access

    The relationship between ASIC3 gene polymorphism and fibromyalgia syndrome

    by Cemile Zontul, Ayca Tas, Emrullah Hayta, Yavuz Silig

    Objectives: Fibromyalgia syndrome (FMS) is a chronic pain syndrome characterized by widespread body pain over a long period, the cause of which is not yet clearly known. FMS patients usually have high pain sensitivity. We aimed to investigate whether rs4148855 and rs2288646 polymorphisms of acid-sensing ion channel 3 ( ASIC3 ), one of the factors contributing to pain, cause a predisposition to FMS in the Turkish population. Methods: ASIC3 gene rs4148855 and rs2288646 polymorphisms in DNA samples obtained from blood samples of 175 patients with FMS and 176 healthy individuals were analyzed by real-time polymerase chain reaction (RT-PCR) using a hydrolysis probe. Statistical data were obtained by chi-square (χ 2 ) test and logistic regression analysis. Results: No significant association was found between ASIC3 gene rs4148855 and rs2288646 polymorphisms and the Turkish population’s FMS group and control group (p>0.05). Conclusions: As a result, no significant association was found between the genotype and allele distributions of ASIC3 polymorphism (rs4148855 and rs2288646) in patients with FMS compared to controls in the Turkish population. Further studies are needed to elucidate the relationship between ion channels and FMS to elucidate the mechanisms of FMS.


  • Open Access

    Serum Calcitonin Gene-Related Peptide and Receptor Protein Levels in Patients With Fibromyalgia Syndrome: A Cross-Sectional Study

    by Ragıp Ulvi KORUCU, Ahmet Karadağ, Ayça Taş, Esma Özmen, Emrullah Hayta, Yavuz Siliğ

    Objectives: This study aims to compare the serum calcitonin gene-related peptide (CGRP) and CGRP receptor protein levels between patients with fibromyalgia syndrome (FM) and healthy control subjects. Patients and methods: The study included 88 patients (7 males, 81 females; mean age 44.5±9.1 years; range, 20 to 72 years) newly-diagnosed with FM according to the 2010 American College of Rheumatology criteria and 88 healthy volunteers (6 males, 82 females; mean age 43.0±6.1 years; range, 20 to 57 years). Venous blood samples were collected from both groups for the measurement of the levels of serum CGRP and CGRP receptor proteins (receptor component protein [RCP], receptor activity modifying protein 1 [RAMP 1] and calcitonin receptor-like receptor [CLR]). Results: A comparison of the serum CGRP, CLR and RCP levels of the FM and control groups revealed a statistically significant difference (p=0.001, p=0.005, p=0.001, respectively). The difference between the groups in respect of the serum RAMP 1 levels was not statistically significant (p=0.107). Conclusion: The serum CGRP, CLR and RCP levels were found to be higher in the FM patients, but no difference was determined between the FM patients and the healthy control group in respect of the RAMP 1 level. These results can be of guidance for further clinical studies of the etiopathogenesis and treatment of FM.


  • Open Access

    Comparison of Beta-2 Adrenergic Receptor Gene Polymorphisms Between Patients with Fibromyalgia Syndrome and Healthy Controls

    by Gözde Şen Çakiroğlu, Sami Hi̇zMetli̇, Yavuz Si̇lİğ, Ahmet Karadağ, Emrullah Hayta, Burcu Özaltin, Ayça Taş, Cemile Zontul

    Objectives: This study aims to compare the beta-2 adrenergic receptor (ADRB2) gene polymorphisms of patients with fibromyalgia syndrome (FMS) with those of healthy control subjects, and to investigate the possible relationship between symptoms of FMS and polymorphisms of the ADRB2 gene. Patients and methods: The study included 170 females (mean age 47.8±10.3 years; range, 21 to 75 years) diagnosed with FMS according to the 2010 American College of Rheumatology criteria and 170 healthy females (mean age 47.2±8.8 years; range, 20 to 72 years) as the control group. Several clinical symptoms of the participants related to FMS were questioned and recorded. The visual analog scale (VAS) and Fibromyalgia Impact Questionnaire (FIQ) scores of the fibromyalgia group were recorded. In both groups, the ADRB2 (rs1042717) single-nucleotide polymorphism was detected by way of a real-time polymerase chain reaction. The wild-type (Guanine/Guanine), the mutant type (Adenine/Adenine) and heterozygous type (Adenine/Guanine) were detected. The sample power was calculated considering the minor allele frequency. Results: The comparison of the ADRB2 gene polymorphism between patients with FMS and the control subjects showed that the groups were similar in terms of ADBR2 gene polymorphism and genotype (p>0.05). There was no significant difference in terms of genotype when the ADRB2 gene polymorphisms in patients with FMS were compared in terms of clinical symptoms, VAS and FIQ scores (p>0.05). Conclusion: Beta-2 adrenergic receptor (rs1042717) gene polymorphisms and genotype distribution are no different between patients with FMS and healthy individuals. ADRB2 gene polymorphisms in patients with FMS have no effect on clinical symptoms and VAS and FIQ scores. The results of the present study will light the way for future research into ADRB2 gene polymorphisms in the pathogenesis of FMS.


  • Evaluation of hearing loss and tinnitus in Behcet’s disease

    by Ahmet Karadağ, Mujde Karadağ, Adem Bora, Emrullah Hayta, A. Bahadır Çetin, Sevil C. Doğan, Kasım Durmuş, E. Elif Altuntaş

    The aim of this study is to evaluate sensorineuralhearing loss (SHNL) and tinnitus in patients with Behcet’s disease (BD), while also determining the association between the clinical symptoms of BD and the disease duration with the development of hearing loss.


  • Open Access

    Decrease of Serum IGF-1 Level is Not Associated With Obstructive Sleep Apnea in Fibromyalgia Patients

    by Emrullah Hayta, Ayşe Altun OKŞAŞOĞLU

    Objectives: This study aims to investigate the relationship of serum insulin-like growth factor 1 (IGF-1) level with obstructive sleep apnea, the Pittsburgh sleep quality index (PSQI), age, body mass index, and fibromyalgia impact questionnaire (FIQ) in fibromyalgia syndrome (FMS) patients. Patients and methods: A total of 105 female patients (mean age 41.8±9.0 years; range 26 to 55 years) with fibromyalgia (FMS group) who were diagnosed according to 2010 American College of Rheumatology criteria, and 51 female patients (mean age 39.9±10.8 years; range 24 to 54 years) with mechanical low back pain (MLBP) (control group) were included in the study. Age, smoking, educational status, tender point number, body mass index, duration of disease, FIQ, PSQI, and polysomnographic assessment of both FMS and control groups were recorded. Results: Sleep disorder was detected in 88 patients in FMS group and 15 patients in control group (p